


Potential new treatments for Huntington's disease



Mutant HTT is increased in HD patient-derived cells using an MSD assay. a Paradigm illustrating the HD patient-based disease model (fibroblasts, iPSC, cortical progenitors (25d old), and cortical neurons (35d old)) and readouts. Created with BioRender.com. b Bar plot depicting FACS quantification of



NESTIN/PAX6 double-positive cells. Statistics: Welch's test. Bars: median ± IQR. c Bar plot illustrating FACS quantification of bIII-Tubulin/CTIP2 doublepositive cells. Statistics: Welch's test. Bars: median ± IQR. d Representative pictures of cortical neurons. Scale bar 50 µm. e Illustration depicting the MSD HTT quantification assay, where the added protein samples bind to 2B7 antibody, used for coating the plates. The SULFO-TAG coupled antibodies D7F7 and MW1 are added for quantification of total HTT and mutant HTT, respectively. Note: numeric values from 2B7/D7F7 assay (total HTT) cannot be directly set in relation to numeric values from 2B7/MW1 assay (mutant HTT). Created with BioRender.com. f Bar plots quantifying total (tHTT, top) and mutant (mHTT, bottom) levels in fibroblasts (4 Ctrl lines, 4 HD lines) with 2B7/D7F7 and 2B7/MW1 MSD assays, respectively. Statistics: tHTT: Welch's test (P value = 0.9717); mHTT Welch's test (P value = 0.0737). Bars: median ± IQR. g Bar plots quantifying total (tHTT, top) and mutant (mHTT, bottom) levels in iPSC (8 Ctrl lines, 9 HD lines) with 2B7/D7F7 and 2B7/MW1 MSD assays, respectively. Statistics: tHTT: Welch's test (P value = 0.2080); mHTT Mann–Whitney test (P value

Citation: Potential new treatments for Huntington's disease (2022, December 8) retrieved 28 April 2024 from https://medicalxpress.com/news/2022-12-potential-treatments-huntington-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.